The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) collects longitudinal data from patients being evaluated for or treating with novel FDA approved therapies for Alzheimer’s disease (AD), and tracks patient health outcomes (clinical response and safety), associated with use in real-world settings. Novel FDA-approved therapies for AD are drugs that have received approval as treatments for Alzheimer's disease (AD) from the U.S. Food and Drug Administration since 2021. ALZ-NET aims to assess the clinical course of individuals from a variety of backgrounds and communities, to achieve representativeness beyond the populations historically enrolled in clinical trials. ALZ-NET is a resource for evidence gathering, information sharing, and education across clinical and research communities, encouraging innovative, inclusive research, and supporting opportunities to improve care.
AIM 1: Establish the necessary network infrastructure:
AIM 2: The registry will develop mechanisms to co-enroll participants in affiliated trials
AIM 3: The registry will collect data to evaluate long term safety, clinical use and outcomes:
AIM 4: Merge and compare ALZ-NET data with existing databases to further understand patient outcomes and resource utilization
AIM 5: Establish and implement infrastructure for sharing of de-identified data, images and biosamples